Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461149 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL1455096 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL1454852 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL2122897 | 1.00 | — | — | |
| SCHEMBL3462577 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL1453375 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL3461175 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL3462205 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL3463066 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 | |
| SCHEMBL3460218 | 1.00 | HSD17B10 (0.33) | HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226632-B1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-02-12 | — | — | EP | disclosed |
| US-8450070-B2 | Method for screening of cell-protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2226632-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-4631143-A | Triphenylene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279311-A1 | METHOD FOR SCREENING OF CELL-PROTECTING AGENT | HSF1, HSP90AB1, HSP90AA1 | HSD17B10 2687/4885TDP1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.